vimarsana.com
Home
Live Updates
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 : vimarsana.com
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
100% of treated leukemia patients achieved durable complete remission at 1-year, including high-risk and relapsed acute myeloid leukemia patients who had previously failed multiple lines of...
Related Keywords
United States
,
Trishna Goswami
,
Glenn Schulman
,
Josephp Mcguirk
,
Drug Administration
,
Exchange Commission
,
Globenewswire Inc
,
University Of Kansas Cancer Center
,
Nasdaq
,
European Hematology Association
,
Hematology Association
,
Dose Level
,
Chief Medical Officer
,
Speas Professor
,
Division Director
,
Hematologic Malignancies
,
Cellular Therapeutics
,
Medical Director
,
Marrow Transplant
,
Kansas Cancer
,
Kansas Cancer Center
,
Private Securities Litigation Reform Act
,
Quarterly Report
,
vimarsana.com © 2020. All Rights Reserved.